JP2007502789A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502789A5
JP2007502789A5 JP2006523576A JP2006523576A JP2007502789A5 JP 2007502789 A5 JP2007502789 A5 JP 2007502789A5 JP 2006523576 A JP2006523576 A JP 2006523576A JP 2006523576 A JP2006523576 A JP 2006523576A JP 2007502789 A5 JP2007502789 A5 JP 2007502789A5
Authority
JP
Japan
Prior art keywords
active substance
characteristic
mass
concentration
drying gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502789A6 (ja
JP2007502789A (ja
Filing date
Publication date
Priority claimed from DE2003138402 external-priority patent/DE10338402A1/de
Application filed filed Critical
Publication of JP2007502789A publication Critical patent/JP2007502789A/ja
Publication of JP2007502789A6 publication Critical patent/JP2007502789A6/ja
Publication of JP2007502789A5 publication Critical patent/JP2007502789A5/ja
Pending legal-status Critical Current

Links

JP2006523576A 2003-08-18 2004-08-12 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用 Pending JP2007502789A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003138402 DE10338402A1 (de) 2003-08-18 2003-08-18 Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402.2 2003-08-18
PCT/EP2004/009012 WO2005018603A2 (de) 2003-08-18 2004-08-12 Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum

Publications (3)

Publication Number Publication Date
JP2007502789A JP2007502789A (ja) 2007-02-15
JP2007502789A6 JP2007502789A6 (ja) 2007-05-10
JP2007502789A5 true JP2007502789A5 (enExample) 2007-09-27

Family

ID=34201781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523576A Pending JP2007502789A (ja) 2003-08-18 2004-08-12 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用

Country Status (5)

Country Link
EP (1) EP1663149A2 (enExample)
JP (1) JP2007502789A (enExample)
CA (1) CA2536047A1 (enExample)
DE (1) DE10338402A1 (enExample)
WO (1) WO2005018603A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) * 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
MD4673C1 (ro) * 2013-06-19 2020-11-30 Aicuris Anti-Infective Cures Gmbh Letermovir amorf şi forme preparative farmaceutice solide ale acestuia pentru administrare orală
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
WO2001056581A1 (en) * 2000-02-04 2001-08-09 Kissei Pharmaceutical Co., Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver

Similar Documents

Publication Publication Date Title
JP2007502789A (ja) 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用
JP2007502789A6 (ja) 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用
US20050043247A1 (en) Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
JP5680898B2 (ja) 苦味を抑制した速崩壊錠
US7833550B2 (en) Dry powder formulations of antihistamine for nasal administration
TWI522130B (zh) 具有改良之安定性的(z)-2-氰基-3-羥基-丁-2-烯酸-(4’-三氟甲基苯基)-醯胺錠劑調配物
US9511026B2 (en) Poorly soluble drug containing microspheres with improved bioavailability and method of preparing the same
US6692768B1 (en) Preparation method of drug-containing spherical fine particles
RU2017115807A (ru) Синтез коллоидных частиц драгоценных металлов с контролируемыми размером и морфологией
ES2279094T3 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp bibn4096.
JP2005538934A5 (enExample)
KR20130082465A (ko) 구강내 필름형 기제 및 제제
DE102009015702A1 (de) Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
JP4444626B2 (ja) 口腔内崩壊錠
JP2008013480A (ja) 薬物含有微粒子およびその製造方法
JP2007502790A5 (enExample)
US20050042178A1 (en) Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
JP5906003B2 (ja) 抗コリン作用薬を含有する安定な粉末製剤
JP4493594B2 (ja) 粉末経鼻投与製剤
JP2007502790A (ja) Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
JP2007502790A6 (ja) Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
CN105440017B (zh) 达比加群酯香草酸盐及其制备方法和应用
JP2007502791A5 (enExample)
JP2010510278A (ja) 新規抗コリン作用薬を含有する安定な粉末製剤
JP2007502792A5 (enExample)